Leukemia, Myeloid, Acute: all 3,035 studies

Page 9 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.

• Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT04478695Phase 1Results posted
• Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid LeukemiaTerminatedNCT04435691Phase 1/2Results posted
• A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-WorldCompletedNCT04337138Results posted
• AflacLL1901 (CHOA-AML)TerminatedNCT04326439Phase 2Results posted
• BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04284787Phase 2Results posted
• Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid LeukemiaCompletedNCT04277442Phase 1Results posted
• A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive ChemotherapyCompletedNCT04266795Phase 2Results posted
• A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedNCT04240002Phase 1/2Results posted
• CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid LeukemiaActive, not recruitingNCT04231851Phase 2Results posted
• BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04214249Phase 2Results posted
• A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid LeukemiaTerminatedNCT04209725Phase 2Results posted
• CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit PatientsCompletedNCT04195945Phase 2Results posted
• Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic MalignanciesCompletedNCT04191187Phase 2Results posted
• A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)TerminatedNCT04161885Phase 3Results posted
• Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT04158739Phase 1Results posted
• A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for ChemotherapyTerminatedNCT04150029Phase 2Results posted
• Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative DiseaseCompletedNCT04146038Phase 2Results posted
• A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional ChemotherapyCompletedNCT04102020Phase 3Results posted
• Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple MyelomaTerminatedNCT04097301Phase 1/2Results posted
• A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)CompletedNCT04079296Phase 1/2Results posted
• Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113CompletedNCT04070768Phase 1Results posted
• Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantationActive, not recruitingNCT04060277Phase 2Results posted
• GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid LeukemiaTerminatedNCT04051996Phase 2Results posted
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid TumorsTerminatedNCT04029688Phase 1/2Results posted
• A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive ChemotherapyActive, not recruitingNCT04023526Phase 2Results posted
• Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AMLTerminatedNCT04002115Phase 2Results posted
• Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid LeukemiaTerminatedNCT03988205Phase 4Results posted
• Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination TherapyTerminatedNCT03969420Phase 2Results posted
• Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) MutationActive, not recruitingNCT03953898Phase 2Results posted
• A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive ChemotherapyCompletedNCT03941964Phase 3Results posted
• APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell TransplantCompletedNCT03931291Phase 2Results posted
• A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid LeukemiaTerminatedNCT03922477Phase 1Results posted
• Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMMLTerminatedNCT03922100Phase 1/2Results posted
• A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTActive, not recruitingNCT03912064Phase 1Results posted
• Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaTerminatedNCT03860844Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete RemissionTerminatedNCT03850535Phase 1/2Results posted
• TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic MalignanciesActive, not recruitingNCT03849651Phase 2Results posted
• Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid LeukemiaCompletedNCT03844997Phase 1/2Results posted
• Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction TherapyCompletedNCT03839446Phase 2Results posted
• Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid LeukemiaCompletedNCT03836209Phase 2Results posted
• A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver ProblemsCompletedNCT03814005Phase 1Results posted
• Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT03813147Phase 1Results posted
• Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT03772925Phase 1Results posted
• Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersCompletedNCT03761914Phase 1/2Results posted
• A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03760666Phase 1/2Results posted
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT03755414Phase 1Results posted
• Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid LeukemiaTerminatedNCT03735875Phase 1/2Results posted
• Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical StudyTerminatedNCT03733249Phase 1/2Results posted
• A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)CompletedNCT03730012Phase 1/2Results posted
• Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene RearrangementTerminatedNCT03724084Phase 1/2Results posted
• AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and MyelofibrosisTerminatedNCT03718143Phase 2Results posted
• Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AMLTerminatedNCT03709576Phase 2Results posted
• Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction ChemotherapyActive, not recruitingNCT03701308Phase 2/3Results posted
• Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 RearrangementCompletedNCT03701295Phase 1/2Results posted
• A Study of FMT in Patients With AML Allo HSCT in RecipientsCompletedNCT03678493Phase 2Results posted
• Trial Evaluating MGTA-456 in Patients With High-Risk MalignancyActive, not recruitingNCT03674411Phase 2Results posted
• Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT03671564Phase 1Results posted
• Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid LeukemiaTerminatedNCT03634228Phase 1/2Results posted
• Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched DonorsTerminatedNCT03615105Phase 2Results posted
• Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)TerminatedNCT03614728Phase 1/2Results posted
• A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi AnemiaTerminatedNCT03600909Phase 2Results posted
• First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic SyndromeTerminatedNCT03594955Phase 1/2Results posted
• Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid LeukemiaCompletedNCT03573024Phase 2Results posted
• JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT03557970Phase 2Results posted
• Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)TerminatedNCT03552029Phase 1Results posted
• Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03541369Phase 1Results posted
• Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell TransplantTerminatedNCT03537599Phase 1/2Results posted
• Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid NeoplasmCompletedNCT03531918Phase 1/2Results posted
• A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)CompletedNCT03512197Phase 3Results posted
• Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' ExpressionCompletedNCT03480360Phase 3Results posted
• Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AMLCompletedNCT03466294Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesTerminatedNCT03465540Phase 1Results posted
• A Dose Optimisation Study of ASLAN003 in Acute Myeloid LeukemiaCompletedNCT03451084Phase 2Results posted
• Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood TransplantationCompletedNCT03434730Phase 2Results posted
• A Study of LAM-003 in Patients With Acute Myeloid LeukemiaCompletedNCT03426605Phase 1Results posted
• Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDSCompletedNCT03417154Phase 2Results posted
• A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT03416179Phase 3Results posted
• OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03390296Phase 1/2Results posted
• Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCNActive, not recruitingNCT03386513Phase 1/2Results posted
• Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.CompletedNCT03379727Phase 3Results posted
• Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03374332Phase 1/2Results posted
• DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT03358719Phase 1Results posted
• Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid LeukemiaCompletedNCT03335267Phase 2Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerTerminatedNCT03333486Phase 2Results posted
• Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03318016Phase 1Results posted
• Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)CompletedNCT03315039Phase 1/2Results posted
• Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AMLCompletedNCT03306264Phase 3Results posted
• Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)CompletedNCT03303339Phase 1/2Results posted
• Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).CompletedNCT03298984Phase 1Results posted
• Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT03289910Phase 2Results posted
• Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With PembrolizumabTerminatedNCT03286114Phase 1Results posted
• A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AMLCompletedNCT03280030Phase 2Results posted
• Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)CompletedNCT03268954Phase 3Results posted
• Epigenetic Reprogramming in Relapse/Refractory AMLCompletedNCT03263936Phase 1Results posted
• Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell TransplantationTerminatedNCT03246906Phase 2Results posted
• Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid LeukemiaCompletedNCT03226418Phase 2Results posted
• Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)TerminatedNCT03224819Early Phase 1Results posted
• GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological MalignanciesTerminatedNCT03214666Phase 1/2Results posted
• Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood DisordersTerminatedNCT03198234Phase 1Results posted
• A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) MutationCompletedNCT03182244Phase 3Results posted

← Leukemia, Myeloid, Acute overview